Purpose: To review immune checkpoint inhibitor indications and ophthalmic side effects.
Methods: A literature review was performed using a PubMed search for publications …

The advent of immunotherapy has heralded a number of significant advances in the
treatment of particular malignancies associated with poor prognosis (melanoma, non-small …

Objective To report the clinicopathologic features and outcome of myositis in patients treated
with immune checkpoint inhibitors (ICIs)(irMyositis). Methods We retrospectively analyzed …

ICI-associated irAEs constitute a new group of neurologic complications of systemic
anticancer therapies. Although potentially severe, these rare neurologic toxicities are often …

Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in
cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad …

Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4,
programmed cell death-1, and PD-ligand 1 have revolutionized cancer treatment, achieving …

Abstract Purpose of Review In recent years, immune checkpoint inhibitors have been
increasingly used in patients with metastatic cancers with favorable oncological outcomes; …

Immunotherapy has emerged in recent years and has revolutionized the treatment of cancer.
Immune checkpoint inhibitors, including anti-cytotoxic T lymphocyte antigen-4 (CTLA-4), anti …

Abstract Purpose of Review Immune checkpoint inhibitors represent a major step forward in
the field of oncologic immunotherapy these last years and have significantly increased …